Biocon, Sandoz partner for immunology and cancer biosimilars' development

Second large global tie-up for an Indian company after Mylan

Kiran Mazumdar-Shaw

Kiran Mazumdar-Shaw

Biocon has signed with Sandoz, the generics arm of the $48.52-billion Swiss Pharma giant Novartis to jointly invest and co-develop, manufacture and market, a new range of biosimilars in immunology

Also Read

Nod for Trastuzumab will open lot of markets: Kiran Mazumdar-Shaw

Biocon secures nod for its first biosimilar in US

Biosimilar can boost Biocon sentiment

Investors cheer Biocon progress; stock gains 230% in past two years

Biocon withdraws applications to sell two cancer drugs in Europe

Can drive in EVs in India by 2020 if infrastructure is ready: Audi

YES Bank posts 22% rise in Q3 net profit at Rs 10.76 bn; NII jumps 27%

ICICI Ventures invests Rs 1 bn in women's legwear brand Go Colors

Retail firm Siam Makro enters cash & carry biz in India, to invest Rs 10 bn

Stopping promoters' bids will severely impact recoveries: Hemant Kanoria

First Published: Jan 18 2018 | 6:32 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers.

Register to